AHSG and metabolic syndrome: Overall, while the precise mechanisms underlying the relationship between fetuin and dyslipidemia are not fully understood, evidence suggests that fetuin A may contribute to dyslipidemia through its effects on lipid metabolism, insulin resistance, and atherosclerosis, making it a potential therapeutic target for managing dyslipidemia and its associated complications [21].